grow hiv revenu stabil hcv revenu
gilead report product revenu beat consensu
y/i non-gaap ep beat consensu though
y/i declin bottom line non-gaap
net incom gilead end quarter cash exclud
associ galapago glpg nr collabor agreement
note link overal view posit quarter bit
surpris compani continu evolv next phase new
revenu guidanc increas manag rais midpoint
revenu guidanc reiter
guidanc gross margin sg
effect tax rate
commerci updat growth driven primarili hiv franchis
expect hiv revenu y/i larg fuel biktarvi
growth us compani continu lose ground
europ truvada gener competitor howev biktarvi eu
launch continu could see trend stabil grow hcv seem
stabil new patient start last quarter
sequenti increas
yescarta growth though sequenti view
gilead less increment said access expand
center come line rememb first indic
first cell therapi product like follow time
said maintain view cell therapi answer gilead
look toward expans pipelin via galapago far
drive long-term growth chang focu view also reflect
high rate turnov upper manag level gilead look
futur
focu futur see long-term growth prospect loss
blockbust hcv franchis near total market domin hiv us
patient anti-retrovir gilead product gilead period chang
manag search new avenu gener growth
hiv compani continu explor new compound capsid
inhibitor agonist part hiv cure research program
post posit earli stage result near term look uptak
biktarvi expans prep drive growth maintain compani market
posit particular descovi prep snda file decis expect could
expand market due improv safeti profil truvada especi
prep user typic healthi
inflammatori anoth space could drive growth gilead
collabor galapago essenti give gilead inflammatori pipelin
option nearli doubl research base filgotinib nearest product
candid nda file expect rheufmatoid arthriti ra
gilead alreadi establish leadership posit hematolog launch
yescarta though program quit blockbust steadi growth
sale past quarter car-t shape smaller signific
franchis especi addit registr trial readout next
month registr studi nhl studi kte-
mcl compani also plan expand earlier line therapi
eventu solid tumor allogen car-t
nash also larg potenti market howev failur stellar
program along sever program around nash space taken
steam space next event nash gilead atla combin
trial test doublet selonsertib firsocostat cilofexor read later
inflammatori diseas next blockbust space gilead gilead
report posit data three finch trial follow talk
fda manta trial longer delay expect timelin filgotinib
rheumatoid arthriti ra nda file expect although
 nr upadacitinib like make market earlier fda
decis like come august prioriti review accept februari
addit olumi xeljanz alreadi market ra
though carri black box warn showdown upadacitinib
filgotinib expect come balanc safeti efficaci
seek approv low dose upadacitinib possibl due increas
herp zoster infect observ higher dose said filgotinib
demonstr superior humira upadacitinib howev
new galapago collabor agreement gilead potenti footprint inflammatori
diseas could expand far beyond ra even filgo filgotinib also
investig ulcer coliti data crohn diseas ankylos
spondyl psoriat arthriti among sever other
late-stag asset gilead commerci right idiopath
pulmonari fibrosi option in-licens osteoarthr
addit earlier stage asset make gilead option
in-licens galapago product candid
model chang adjust revenu increas guidanc
place total revenu increas non-gaap ep
exhibit guidanc increas
exhibit biktarvi regimen among patient us nave patient eu
exhibit us market dynam hiv
exhibit gilead us share treatment nave hiv patient
exhibit truvada prep continu grow us note descovi prep could help gilead increas
adopt prep market due improv safeti
exhibit descovi prep trial demonstr superior safeti truvada
exhibit hcv show sign stabil
exhibit hcv patient initi sovaldi-bas regimen stabl four quarter
pipelin asset focu
exhibit finch data demonstr posit efficaci filgotinib
thousand except per share data
contract revenu
cog associ car-t
royalti merck us sale harvoni sovaldi
interest incom net
net loss attribut non control interest
net incom attribut gilead
basic ep attribut gilead sharehold
gaap dilut ep attribut gilead sharehold
compani report maxim group estim
